Of 10 guidance figures from Gilead Sciences's earnings releases that Stock Atlas has scored against the reported result, 8 came in above the guide, 0 in range and 2 below. It met or beat its own guidance 80% of the time.
| Period | Measure | Guided | Reported | Result |
|---|---|---|---|---|
| FY2025 | Operating Income | $10.30B to $10.60B | $10.02B | below |
| FY2025 | Revenue | $28.40B to $28.70B | $29.44B | above |
| FY2024 | Operating Income | $1.10B to $1.40B | $1.66B | above |
| FY2024 | Revenue | $27.80B to $28.10B | $28.75B | above |
| FY2023 | Operating Income | $10.50B to $10.80B | $7.61B | below |
| FY2023 | Total product sales | $26.70B to $26.90B | $27.12B | above |
| FY2022 | Total product sales | $25.90B to $26.20B | $27.28B | above |
| FY2021 | Total product sales | $26.00B to $26.30B | $27.30B | above |
Above means the reported figure beat the top of the range, in range that it landed inside it or on a point guide, below that it missed. Every guide and revision, and screens across companies, are in the research platform.
Do companies beat their own guidance? The study · Back to Gilead Sciences financials
The week's biggest guidance misses, KPI surprises and one chart.
Stock Atlas, “Gilead Sciences (GILD) guidance record”, stockatlas.com/companies/GILD/guidance/, data as of 3 November 2026. Links to this page are welcome.
